Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40

Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
LeMaitre Acquires New Jersey-based Medical Device Firm

LeMaitre Acquires New Jersey-based Medical Device Firm

LeMaitre Vascular (NASDAQ: LMAT), a Massachusetts-based medical device manufacturer, announced a new addition to its portfolio. The company has purchased Artegraft, Inc., which processes and sells biologic vascular grafts that are derived from bovine carotid arteries and are implanted primarily in hemodialysis access patients. Its products are marketed under the brand Artegraft and are sold only in the U.S. Artegraft generated trade sales of $15.6 million and estimated hospital-level sales of $18.6 million during the twelve-month period ended May 31, 2020. Artegraft’s unit sales grew by 10% in 2019. LeMaitre purchased Artegraft for a total of $72.5 million in cash, with $65 million upfront... Read More »
Health Care M&A Deals, June 26, 2020

Health Care M&A Deals, June 26, 2020

The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal announcement of the week was Invitae Corporation’s acquisition of ArcherDX, a genomic sequencing services company, for $883.3 million. To subscribe to our Health Care M&A deals chart and more, visit our membership site. HealthCareMandA.com is devoted to healthcare merger and acquisition data for the serious analyst and investor. Every day, this service... Read More »
Sanofi Pasteur Jumps Into the COVID-19 Vaccine Race

Sanofi Pasteur Jumps Into the COVID-19 Vaccine Race

Sanofi Pasteur, the vaccine division of Sanofi (NYSE: SNY) has expanded its partnership with Translate Bio (NASDAQ: TBIO ) to produce a COVID-19 vaccine. The two companies are pursuing novel mRNA vaccines aimed at broadly addressing current and future infectious diseases, evaluating multiple COVID-19 vaccine candidates. They hope to conduct human clinical trials in Q4:2020 but are also advancing an mRNA vaccine development candidate against influenza through preclinical studies with clinical trial initiation anticipated in mid-year 2021. The original agreement dates back to 2018, when Translate Bio and Sanofi Pasteur entered into a collaboration and exclusive license agreement to develop... Read More »
Penn State Health Adds Holy Spirit Health

Penn State Health Adds Holy Spirit Health

For the first time in a few years, Penn State Health is adding another hospital system. The Hershey, Pennsylvania-based not-for-profit signed a definitive agreement to acquire Holy Spirit Health System from Geisinger Health System, another large not-for-profit system based in Danville, Pennsylvania. Geisinger acquired Holy Spirit Health in October 2014. Holy Spirit is anchored by Holy Spirit Hospital (277 beds), a Level II Trauma Center located in Camp Hill, Pennsylvania, southwest of Harrisburg. The deal includes the hospital, its outpatient practices and urgent care centers in Cumberland, Dauphin, Perry and York counties, as well as the Ortenzio Heart Center and the assets of West Shore... Read More »
Invitae Corporation Grows Diagnostics Platform With New Acquisition

Invitae Corporation Grows Diagnostics Platform With New Acquisition

Invitae Corporation (NYSE: NVTA), a genetic information company, announced on June 22 it acquired Colorado-based ArcherDX for $883.3 million. ArcherDX offers genomic sequencing services and testing solutions to help develop and deliver personalized and precision diagnostics and monitoring in the field of oncology. Invitae will pay $325 million in cash and 30 million shares of Invitae common shares at $18.61 per share (June 19, 2020 closing price). In addition, up to 27 million shares of Invitae stock could be payable upon milestone achievements   The combined company will be able to offer robust support for biopharmaceutical companies, from patient identification and screening to biomarker... Read More »
Takeda Makes Another Divestment

Takeda Makes Another Divestment

In another sale to lighten its portfolio, Takeda Pharmaceuticals (OTCMKTS: TKPHF) has announced the divestiture of 18 prescription and over-the-counter brands. Celltrion (KRX:068270), a South Korean-based biotechnology company, purchased the assets for $278.3 million. The assets are distributed in a number of markets in the Asian-Pacific region, including South Korea, Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia, and Australia. The assets from Takeda in the deal grossed a combined sale of approximately $140 million in 2018. The portfolio includes Nesina and Actos (both for diabetes), Edarbi (hypertension), and well-known OTC products. Nesina and Edarbi are... Read More »
MTBC Adds Meridian Medical to Boost Healthcare IT

MTBC Adds Meridian Medical to Boost Healthcare IT

MTBC (NASDAQ: MTBC) has announced a new acquisition, significantly expanding its revenue cycle management (RCM) and healthcare IT capabilities. The company revealed on June 17 it purchased Meridian Medical Management, a healthcare IT company that delivers advanced healthcare information technology solutions and RCM services to thousands of healthcare providers nationwide. Gores Meridian Medical Holdings, LLC (Gores) has been the owner of Meridian (f.k.a GE Healthcare Strategic Sourcing) since 2013 when it purchased the company from GE Healthcare for an undisclosed price. Gores is selling Meridian for $19.8 million. The price breaks down to $15 million cash and the assumption of $4.8... Read More »
Bravo Wellness Moves Into Performance-Based Wellness Market

Bravo Wellness Moves Into Performance-Based Wellness Market

On June 18 Bravo Wellness announced the acquisition of Push, a Chicago-based managed care company, for an undisclosed sum. Founded in 2008, Bravo Wellness provides employers and health plans with configurable employee wellness programs that can strengthen employee benefits and drive down long-term claims. The company has about two million members. Bravo is looking to compete in the performance-based wellness market, and Push would give them an advantage. Launched in 2011, Push leverages technology and behavioral economics to motivate people to improve their health, producing real benefits for health plans, self-insured employers, and their valued members. It also specializes in developing... Read More »
Health Care M&A Deals, June 26, 2020

Health Care M&A Deals, June 19, 2020

The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal announcement of the week was Lee Equity Partners’ acquisition of Integrated Medical Professionals and The Urology Group for and estimated $240 million. To subscribe to our Health Care M&A deals chart and more, visit our membership site. HealthCareMandA.com is devoted to healthcare merger and acquisition data for the serious... Read More »
Lee Equity Partners Forms New Urology Group

Lee Equity Partners Forms New Urology Group

Lee Equity Partners (LEP) announced on June 17 the acquisition of Integrated Medical Professionals (IMP) and The Urology Group (TUG) to form Solaris Health, a management services organization. According to the release from LEP, it will be one of the nation’s largest providers of urological and other specialty services. LEP plans to use Solaris Health as the foundation for a national platform that attracts leading independent urological partners. For the two practices, LEP spent roughly $240 million, according to sources cited in PE HUB. TUG and IMP have combined estimated revenue of $270 million and $25 million in EBITDA. IMP is a urology-centric multi-specialty practice with 81... Read More »